Nitto Denko Corporation, a leading Japanese company in the diversified materials market, announced the creation of Nitto BioPharma, a new company aimed to focus on pharmaceutical development and on the establishment of drug discovery and development ventures. The company’s first anti-liver fibrosis drug program (ND-L02-s0201) is currently in clinical trials in the US, Europe and Japan; the pipeline covers also intractable diseases in the discovery stage.
Kageshi Maruyama is the president of the new company; he is also senior vice president of Nitto Denko Corp. Nitto plans also to set up a new facility in the center of the Life Sciences hub in San Diego, California.